| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.16 | 0.005 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.005 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.007 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |